Global Rheumatoid Arthritis Drugs Market - Symptomatic and DMARDs 2014 2018
RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA.
Vendors in the market are spending on R&D for the development of advanced drugs for the treatment of RA. For instance, Arthritis Foundation’s Research Program in RA focuses on discovering and developing tools that will allow physicians to apply personalized treatment plans for individuals with RA. The goals of this program include determination of the drugs that are most effective for specific patients based on progression, and genetics; and development of strategies and treatments that are expected to inhibit the long-term effects of the disease.
Analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018.
Complete report of 94 Pages is available @ http://www.reportsnreports.com/reports/292215-global-rheumatoid-arthritis-drugs-market-2014-2018.html.